NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...

Prostate cancer screening for men over 70 is complex, with current recommendations against routine PSA testing due to slow ...

Researchers found that patients who took statins alongside apalutamide and standard hormone therapy had higher three-year ...

Prostate cancer is the second most common cancer diagnosis in men. 1 in 8 men will be diagnosed with the disease during their ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has dosed the first patient in a Phase ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has dosed the first patient in a Phase 1 clinical trial of TLX090 (153Samarium (Sm)-DOTMP), a therapeutic ...

A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with ...

A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...

The 82-year-old was diagnosed with an aggressive form of prostate cancer in May. His daughter celebrated his successful ...

A targeted drug combination delays advanced prostate cancer in men with specific DNA repair gene mutations. A large international study led by researchers at UCL has found that a new combination of dr ...

“As part of a treatment plan for prostate cancer, President Biden is currently undergoing radiation therapy and hormone ...

A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.